Serotonin 2 Agonist

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 10029 Experts worldwide ranked by ideXlab platform

Daniel Hell - One of the best experts on this subject based on the ideXlab platform.

  • psilocybin induces schizophrenia like psychosis in humans via a Serotonin 2 Agonist action
    Neuroreport, 1998
    Co-Authors: Franz X Vollenweider, M F I Vollenweiderscherpenhuyzen, Andreas Babler, Helen Vogel, Daniel Hell
    Abstract:

    Psilocybin, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the Serotonin-2A antAgonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antAgonist and typical antipsychotic haloperidol. These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to Serotonin-2A receptor activation, independently of dopamine stimulation. Thus, Serotonin-2A overactivity may be involved in the pathophysiology of schizophrenia and Serotonin-2A antagonism may contribute to therapeutic effects of antipsychotics. Language: en

Franz X Vollenweider - One of the best experts on this subject based on the ideXlab platform.

  • psilocybin induces schizophrenia like psychosis in humans via a Serotonin 2 Agonist action
    Neuroreport, 1998
    Co-Authors: Franz X Vollenweider, M F I Vollenweiderscherpenhuyzen, Andreas Babler, Helen Vogel, Daniel Hell
    Abstract:

    Psilocybin, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the Serotonin-2A antAgonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antAgonist and typical antipsychotic haloperidol. These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to Serotonin-2A receptor activation, independently of dopamine stimulation. Thus, Serotonin-2A overactivity may be involved in the pathophysiology of schizophrenia and Serotonin-2A antagonism may contribute to therapeutic effects of antipsychotics. Language: en

Helen Vogel - One of the best experts on this subject based on the ideXlab platform.

  • psilocybin induces schizophrenia like psychosis in humans via a Serotonin 2 Agonist action
    Neuroreport, 1998
    Co-Authors: Franz X Vollenweider, M F I Vollenweiderscherpenhuyzen, Andreas Babler, Helen Vogel, Daniel Hell
    Abstract:

    Psilocybin, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the Serotonin-2A antAgonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antAgonist and typical antipsychotic haloperidol. These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to Serotonin-2A receptor activation, independently of dopamine stimulation. Thus, Serotonin-2A overactivity may be involved in the pathophysiology of schizophrenia and Serotonin-2A antagonism may contribute to therapeutic effects of antipsychotics. Language: en

M F I Vollenweiderscherpenhuyzen - One of the best experts on this subject based on the ideXlab platform.

  • psilocybin induces schizophrenia like psychosis in humans via a Serotonin 2 Agonist action
    Neuroreport, 1998
    Co-Authors: Franz X Vollenweider, M F I Vollenweiderscherpenhuyzen, Andreas Babler, Helen Vogel, Daniel Hell
    Abstract:

    Psilocybin, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the Serotonin-2A antAgonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antAgonist and typical antipsychotic haloperidol. These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to Serotonin-2A receptor activation, independently of dopamine stimulation. Thus, Serotonin-2A overactivity may be involved in the pathophysiology of schizophrenia and Serotonin-2A antagonism may contribute to therapeutic effects of antipsychotics. Language: en

Andreas Babler - One of the best experts on this subject based on the ideXlab platform.

  • psilocybin induces schizophrenia like psychosis in humans via a Serotonin 2 Agonist action
    Neuroreport, 1998
    Co-Authors: Franz X Vollenweider, M F I Vollenweiderscherpenhuyzen, Andreas Babler, Helen Vogel, Daniel Hell
    Abstract:

    Psilocybin, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the Serotonin-2A antAgonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antAgonist and typical antipsychotic haloperidol. These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to Serotonin-2A receptor activation, independently of dopamine stimulation. Thus, Serotonin-2A overactivity may be involved in the pathophysiology of schizophrenia and Serotonin-2A antagonism may contribute to therapeutic effects of antipsychotics. Language: en